Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy Extension Study of ONO-4641 in Relapsing-Remitting Multiple Sclerosis
2010-018705-11Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceralifimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck Serono. Primary endpoints: MRI gadolinium-enhancing lesion count, MRI lesion volume and 1 more. Started Jul 2010; status: completed.
02
Drugs
ceralifimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2010-018705-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018705-11.